In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has experienced a notable downturn, touching a 52-week low of $666.With a market capitalization of $71.55 billion and a P/E ratio of 15.6x, this ...

Regeneron stock touches 52-week low at $666 amid market shifts ...

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Regeneron stock touches 52-week low at $641.91 amid market shifts ...

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%. The stock has underperformed the sector and the S&P 500 ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is trading in the red premarket ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in global sales, which consisted ...

One stock in particular has grabbed my attention during this selloff. Regeneron's decline has been epic, and now may be the time to buy. Regeneron's stock, REGN, was taken to the woodshed.

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher ... a powerful factor that could impact its near-term stock price. The earnings report, which is expected ...